EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study

Hazem Abosheaishaa iD, Khaled Elfert iD, Mohammed Abusuliman iD, Abdellatif Ismail iD, Abdullah Olimy iD, Ahmed Elsayed Alzamzamy iD, Ahmed Omran iD, Vincent Rizzo iD, Mahmoud Nassar iD, Mohamed El-Kassas iD

Liver International · 2026

DOI: 10.1111/liv.70843 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Hazem Abosheaishaa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Queens, New York, USA. Hauptthemen laut MEDLINE: Hypertension, Portal, Adrenergic beta-Antagonists, Liver Cirrhosis, Portal Vein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Portal vein thrombosis (PVT) is a significant complication of cirrhosis. Nonselective beta‐blockers (NSBBs) are standard therapy for portal hypertension, but their effect on PVT risk remains uncertain.

Aim

To assess whether NSBB use after variceal band ligation increases PVT risk and to compare outcomes among propranolol, carvedilol and no NSBB therapy.

Methods

We conducted a retrospective cohort study using the TriNetX US Collaborative Network (> 110 million patients). Adults with cirrhosis and portal hypertension who underwent variceal band ligation (2010–2024) were included. Patients were stratified by NSBB exposure and matched 1:1 on 12 clinical variables. The primary outcome was incident PVT; secondary outcome was all‐cause mortality. Kaplan–Meier analysis evaluated time‐to‐event outcomes.

Results

After matching ( n = 4296 per group), NSBB use was associated with higher PVT incidence compared with no NSBBs (9.5% vs. 5.4%; RR 1.765, 95% CI 1.500–2.077). Propranolol was associated with increased PVT risk, whereas carvedilol showed similar PVT incidence to controls and significantly lower mortality compared with both propranolol and no NSBB use.

Conclusions

Propranolol use was linked to increased PVT risk, while carvedilol did not elevate PVT risk and was associated with improved survival. Beta‐blocker selection may meaningfully influence outcomes in cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalAdrenergic beta-AntagonistsLiver CirrhosisPortal VeinVenous ThrombosisHumansRetrospective StudiesPropranololCarvedilolFemaleMiddle AgedMaleEsophageal and Gastric VaricesIncidenceLigationRisk FactorsKaplan-Meier EstimateAged

Substanzen

Adrenergic beta-AntagonistsPropranololCarvedilol

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, Queens, New York, USA.
  • Department of Gastroenterology, West Virginia University, Morgantown, West Virginia, USA.
  • Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
  • Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic-Florida, Weston, USA.
  • Faculty of Medicine, Menoufia University, Menoufia Governorate, Shebin El-Kom, Egypt.
  • Department of Gastroenterology and Hepatology, Maadi Armed Forces Medical Complex, Military Medical Academy, Cairo, Egypt.

ORCID-Profile: Hazem Abosheaishaa, Khaled Elfert, Mohammed Abusuliman, Abdellatif Ismail, Abdullah Olimy, Ahmed Elsayed Alzamzamy, Ahmed Omran, Vincent Rizzo, Mahmoud Nassar, Mohamed El-Kassas

Zitieren

APA

Abosheaishaa, H., Elfert, K., Abusuliman, M., Ismail, A., Olimy, A., Alzamzamy, A. E., Omran, A., Rizzo, V., Nassar, M., & El-Kassas, M. (2026). Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study. Liver International. https://doi.org/10.1111/liv.70843

Vancouver

Abosheaishaa H, Elfert K, Abusuliman M, Ismail A, Olimy A, Alzamzamy AE, et al. Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study. Liver International. 2026. doi:10.1111/liv.70843

BibTeX
@article{Abosheaishaa2026,
  author = {Abosheaishaa, Hazem and Elfert, Khaled and Abusuliman, Mohammed and Ismail, Abdellatif and Olimy, Abdullah and Alzamzamy, Ahmed Elsayed and Omran, Ahmed and Rizzo, Vincent and Nassar, Mahmoud and El-Kassas, Mohamed},
  title = {Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70843}
}
Kostenlos starten →